ANN ARBOR, Mich. & HENDERSON, Nev., March 3, 2026
Esperion Therapeutics and Corstasis Therapeutics Inc. announced a definitive agreement under which Esperion will acquire Corstasis, expanding its cardiovascular franchise with Enbumyst™ (bumetanide nasal spray), the first and only FDA-approved nasal spray loop diuretic for edema associated with congestive heart failure (CHF). The transaction includes an upfront cash payment of $75 million, up to $180 million in potential regulatory and commercial milestone payments, and low double-digit royalties on worldwide Enbumyst sales. The deal is expected to close in the second quarter of 2026, subject to customary conditions.
Strategic Expansion of Cardiovascular Franchise
Enbumyst received U.S. FDA approval in September 2025 for the treatment of edema associated with congestive heart failure, hepatic disease, and renal disease, including nephrotic syndrome in adults. The therapy offers a self-administered intranasal delivery route, designed to bridge the gap between oral and intravenous diuretic treatments in outpatient settings.With an estimated 6.7 million American adults living with CHF, edema remains one of the most common and burdensome clinical features of advanced heart failure. Esperion expects Enbumyst to leverage its established U.S. cardiovascular commercial infrastructure, targeting a market opportunity exceeding $4 billion.
The acquisition aligns with Esperion’s Vision 2040 strategy, focused on delivering differentiated and accessible cardiovascular innovations for high-need populations. By integrating Enbumyst into its commercial platform, Esperion aims to accelerate double-digit revenue growth while strengthening its position across cardiometabolic and renal disease segments.
Financial Structure and Commercial Outlook
Advertisement
Under the terms of the agreement, Esperion will acquire all outstanding shares of Corstasis through a subsidiary in exchange for the $75 million upfront consideration. Additional milestone payments totaling up to $180 million are contingent upon achieving specific regulatory and commercial benchmarks. The acquisition will be financed through existing credit facilities and royalty monetization arrangements
Corstasis is also advancing a subcutaneous pipeline, including a multidose pen injector platform that may unlock further market expansion opportunities. Clinicians have highlighted the potential of Enbumyst’s novel intranasal delivery to provide more rapid and flexible fluid management at home, potentially reducing hospitalizations associated with worsening heart failure symptoms.
Regulatory and Safety Profile
Enbumyst is indicated for adult patients with edema linked to CHF, hepatic, and renal disease. As a loop diuretic, it carries important safety considerations, including risks of fluid and electrolyte imbalance, dehydration, and metabolic abnormalities, consistent with the pharmacological class. The product’s regulatory approval and established safety profile position it as a commercially ready asset within Esperion’s expanding therapeutic portfolio.
The transaction underscores continued consolidation within the cardiovascular biopharmaceutical sector, as companies seek to strengthen pipelines with differentiated, FDA-approved therapies that address high-prevalence chronic conditions. By combining commercial-stage innovation with scalable infrastructure, Esperion’s acquisition of Corstasis reflects a strategic push to broaden its cardiovascular leadership and enhance long-term shareholder value.
Source: Esperion Therapeutics, Corstasis Therapeutics press release
